ArticleBMC health services research2025
Cadonilimab plus chemotherapy compared to chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer in China: a cost-effectiveness analysis.
Longfeng Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.